Biotech Values

[tinkershaw]

<<<Canaccord screwed up by writing that. M356 (generic Copaxone) is a 50/50 profit split between NVS and MNTA regardless of the number of generics in the market.>>>

That is what I thought. Have to start trusting myself over these brokerages that keep doing stupid things. So even in the multiple generic scenario for Copaxone (which is less likely to exist than with Lovenox) the M356 valuation has to exceed Lovenox (asuming approval). If a generic Lovenox (with multiple generics) is worth $13 using their assumptions, then an approved M356 is worth quite a bit more, even in the multiple generic scenario.

My rules for biotech investing start with know the drug works, know the drug works very well, and what is their back up. MNTA is meeting these criteria in spades.

Thanks Dew.

Tinker